The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Targeting the Tumor Microenvironment for Cancer Therapy
Abstract
BACKGROUND: With the emergence of the tumor microenvironment as an essential ingredient of cancer malignancy, therapies targeting the host compartment of tumors have begun to be designed and applied in the clinic. CONTENT: The malignant features of cancer cells cannot be manifested without an important interplay between cancer cells and their local environment. The tumor infiltrate composed of immune cells, angiogenic vascular cells, lymphatic endothelial cells, and cancer-associated fibroblastic cells contributes actively to cancer progression. The ability to change these surroundings is an important property by which tumor cells are able to acquire some of the hallmark functions necessary for tumor growth and metastatic dissemination. Thus in the clinical setting the targeting of the tumor microenvironment to encapsulate or destroy cancer cells in their local environment has become mandatory. The variety of stromal cells, the complexity of the molecular components of the tumor stroma, and the similarity with normal tissue present huge challenges for therapies targeting the tumor microenvironment. These issues and their interplay are addressed in this review. After a decade of intensive clinical trials targeting cellular components of the tumor microenvironment, more recent investigations have shed light on the important role in cancer progression played by the noncellular stromal compartment composed of the extracellular matrix. SUMMARY: A better understanding of how the tumor environment affects cancer progression should provide new targets for the isolation and destruction of cancer cells via interference with the complex crosstalk established between cancer cells, host cells, and their surrounding extracellular matrix.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
Mammographic Density and the Risk and Detection of Breast Cancer
Boyd, N. F., Guo, H., Martin, L. J., Sun, L., Stone, J., Fishell, E., Jong, R. A., Hislop, G., Chiarelli, A., Minkin, S., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062790 · Cited by 2,478
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Tumour necrosis factor and cancer
Balkwill, F. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2628 · Cited by 1,915
DeNardo, D. G., Barreto, J. B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., & Coussens, L. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.018 · Cited by 1,353
Glioblastoma stem-like cells give rise to tumour endothelium
Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K. E., Geber, A., Fligelman, B., Leversha, M., Brennan, C., & Tabar, V. (2010) · Nature · doi:10.1038/nature09624 · Cited by 1,203
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61226-9 · Cited by 797
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
Cancer associated fibroblasts (CAFs) in tumor microenvironment
Xing, F. (2010) · Frontiers in Bioscience · doi:10.2741/3613 · Cited by 682
Greten, F. R., Arkan, M. C., Bollrath, J., Hsu, L.-C., Goode, J., Miething, C., Göktuna, S. I., Neuenhahn, M., Fierer, J., Paxian, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.009 · Cited by 616
Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611
The rationale for targeting the LOX family in cancer
Barker, H. E., Cox, T. R., & Erler, J. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3319 · Cited by 590
Samuel, M. S., Lopez, J. I., McGhee, E. J., Croft, D. R., Strachan, D., Timpson, P., Munro, J., Schröder, E., Zhou, J., Brunton, V. G., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.008 · Cited by 541
Karagiannis, G. S., Poutahidis, T., Erdman, S. E., Kirsch, R., Riddell, R. H., & Diamandis, E. P. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0307 · Cited by 507
Shojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902280106 · Cited by 471
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Huang, D., Ding, Y., Zhou, M., Rini, B. I., Petillo, D., Qian, C.-N., Kahnoski, R., Futreal, P. A., Furge, K. A., & Teh, B. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3965 · Cited by 417
M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis
Kubota, Y., Takubo, K., Shimizu, T., Ohno, H., Kishi, K., Shibuya, M., Saya, H., & Suda, T. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081605 · Cited by 388
Meyer, C., Sevko, A., Ramacher, M., Bazhin, A. V., Falk, C. S., Osen, W., Borrello, I., Kato, M., Schadendorf, D., Baniyash, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108121108 · Cited by 346
The urokinase plasminogen activator system: a target for anti-cancer therapy
Ulisse, S., Baldini, E., Sorrenti, S., & D'Armiento, M. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787314002 · Cited by 312
Van de Veire, S., Stalmans, I., Heindryckx, F., Oura, H., Tijeras-Raballand, A., Schmidt, T., Loges, S., Albrecht, I., Jonckx, B., Vinckier, S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.039 · Cited by 256
ID genes mediate tumor reinitiation during breast cancer lung metastasis
Gupta, G. P., Perk, J., Acharyya, S., de Candia, P., Mittal, V., Todorova-Manova, K., Gerald, W. L., Brogi, E., Benezra, R., & Massagué, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709185104 · Cited by 247
Lust, J. A., Lacy, M. Q., Zeldenrust, S. R., Dispenzieri, A., Gertz, M. A., Witzig, T. E., Kumar, S., Hayman, S. R., Russell, S. J., Buadi, F. K., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.2.114 · Cited by 246
Functional Roles of Human Kallikrein-related Peptidases
Sotiropoulou, G., Pampalakis, G., & Diamandis, E. P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.027946 · Cited by 240
Brennen, W. N., Rosen, D. M., Wang, H., Isaacs, J. T., & Denmeade, S. R. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs336 · Cited by 188
Hammers, H. J., Verheul, H. M., Salumbides, B., Sharma, R., Rudek, M., Jaspers, J., Shah, P., Ellis, L., Shen, L., Paesante, S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1106 · Cited by 173
Miles, D., Harbeck, N., Escudier, B., Hurwitz, H., Saltz, L., Van Cutsem, E., Cassidy, J., Mueller, B., & Sirzén, F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2794 · Cited by 158
Motrescu, E. R., Blaise, S. A., Etique, N., Messaddeq, N., Chenard, M.-P., Stoll, I., Tomasetto, C., & Rio, M. C. (2008) · Oncogene · doi:10.1038/onc.2008.218 · Cited by 133
New and Paradoxical Roles of Matrix Metalloproteinases in the Tumor Microenvironment
Noël, A., Gutiérrez‐Fernández, A., Sounni, N. E., Behrendt, N., Maquoi, E., Lund, I. K., Cal, S., Høyer‐Hansen, G., & López-Otı́n, C. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00140 · Cited by 116
Self-citationFan, F., Samuel, S., Gaur, P., Lu, J., Dallas, N. A., Xia, L., Bose, D., Ramachandran, V., & Ellis, L. M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.81 · Cited by 109
Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase
Detry, B., Erpicum, C., Paupert, J., Blacher, S., Maillard, C., Bruyére, F., Pendeville, H., Remacle, T. Y., Lambert, V., Balsat, C., et al. (2012) · Blood · doi:10.1182/blood-2011-12-400267 · Cited by 95
Bäuerle, T., Komljenovic, D., Merz, M., Berger, M. R., Goodman, S. L., & Semmler, W. (2010) · International Journal of Cancer · doi:10.1002/ijc.25563 · Cited by 84
MMP13 is potentially a new tumor marker for breast cancer diagnosis
Lin, �. �. (2009) · Oncology Reports · doi:10.3892/or_00000544 · Cited by 78
Izzo, J. G., Correa, A. M., Wu, T., Malhotra, U., Chao, C., Luthra, R., Ensor, J., Dekovich, A. A., Liao, Z. X., Hittelman, W. N., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0351 · Cited by 64
Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells
Kang, J., Song, K., Jeong, K., Kim, S., Choi, C., Lee, C. H., & Oh, S. H. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-334 · Cited by 53
Lecomte, J., Masset, A., Blacher, S., Maertens, L., Gothot, A., Delgaudine, M., Bruyére, F., Carnet, O., Paupert, J., Illemann, M., et al. (2012) · Neoplasia · doi:10.1593/neo.121092 · Cited by 41
Cited by
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066
“as well as non-cellular components including ECM, cytokines, and other mediators.(109) Thus, in hypoxic tumor tissue, not only cancer cells but also the tumor microenvironment is affected by hypoxia-inducible changes.”
BackgroundTumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“Due to the compelling role of TME in malignancy, many efforts are focused on this area [15, 16] .”
BackgroundTargeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187
Iron Oxide Based Nanoparticles for Multimodal Imaging and Magnetoresponsive Therapy
Lee, N., Yoo, D., Ling, D., Cho, M. H., Hyeon, T., & Cheon, J. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00112 · Cited by 1,005
Fang, T., Lv, H., Lv, G., Li, T., Wang, C., Han, Q., Yu, L., Su, B., Guo, L., Huang, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02583-0 · Cited by 995
Metadata
- Authors
- Sounni, N. E., & Noel, A.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-01-01
- Volume
- 59
- Issue
- 1
- Pages
- 85-93
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2067274009
- Cited by
- 344
- References
- 40
- FWCI
- 11.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.